Japanese Journal of Clinical Oncology, Vol 27, Issue 1 22-25, Copyright © 1997 by Foundation for Promotion of Cancer Research
M Asamoto, Y Iwahori, T Okamura, T Shirai and H Tsuda
The p16 (CDKN2,MTS1) gene is located at 9p21 and its product, p16, inhibits
the cyclin D/CDK4 complex. Loss of heterozygosity on chromosome 9p is very
common in human bladder carcinomas and has been found in all stages of
lesions, suggesting that it occurs early in bladder tumor progression.
Several studies have revealed frequent homozygous deletion of the p16 gene
in cell lines, and that such deletions are also common in some types of
cancers. In addition, point mutations in the p16 gene have been identified
in several types of neoplasia. In the present examination of urinary
bladder tumors, no p16 gene mutations were detected, but nine cases out of
23 (39%) showed decreased mRNA expression, revealed by the reverse
transcriptase polymerase chain reaction. There were no histological
differences apparent between those cases with normal and those with
decreased p16 expression. These results indicate that while p16 gene
mutations may be rare, changes in the level of the p16 transcripts could
play a role in human bladder carcinoma development.
ORIGINAL ARTICLE
Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas
Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. J. Chapman, P. Harnden, P. Chambers, C. Johnston, and M. A. Knowles Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype Clin. Cancer Res., August 15, 2005; 11(16): 5740 - 5747. [Abstract] [Full Text] [PDF]
|
|